Adverse drug reactions (ADRs) are unintended and harmful reactions caused by normal uses of drugs. Predicting and preventing ADRs in the early stage of the drug development pipeline can help to enhance drug safety and reduce financial costs. In this paper, we developed machine learning models including a deep learning framework which can simultaneously predict ADRs and identify the molecular substructures associated with those ADRs without defining the substructures a-priori. We evaluated the performance of our model with ten different state-of-the-art fingerprint models and found that neural fingerprints from the deep learning model outperformed all other methods in predicting ADRs. Via feature analysis on drug structures, we identified important molecular substructures that are associated with specific ADRs and assessed their associations via statistical analysis. The deep learning model with feature analysis, substructure identification, and statistical assessment provides a promising solution for identifying risky components within molecular structures and can potentially help to improve drug safety evaluation.
Heart failure (HF) prevalence is increasing and is among the most costly diseases to society. Early detection of HF would provide the means to test lifestyle and pharmacologic interventions that may slow disease progression and improve patient outcomes. This study used structured and unstructured data from electronic health records (EHR) to predict onset of HF with a particular focus on how prediction accuracy varied in relation to time before diagnosis. EHR data were extracted from a single health care system and used to identify incident HF among primary care patients who received care between 2001 and 2010. A total of 1,684 incident HF cases were identified and 13,525 controls were selected from the same primary care practices. Models were compared by varying the beginning of the prediction window from 60 to 720 days before HF diagnosis. As the prediction window decreased, the performance [AUC (95% CIs)] of the predictive HF models increased from 65% (63%-66%) to 74% (73%-75%) for the unstructured, from 73% (72%-75%) to 81% (80%-83%) for the structured, and from 76% (74%-77%) to 83% (77%-85%) for the combined data.
Diabetes is a chronic disease that often results in multiple complications. Risk prediction and profiling of diabetes complications is critical for improved outcomes. In this paper, focusing on Type 2 diabetes mellitus (T2DM), we study the risk of developing complications after the initial T2DM diagnosis from longitudinal patient records. We propose a novel multi-task learning approach to simultaneously model multiple complications where each task corresponds to the risk modeling of one complication. Specifically, the proposed method strategically captures the relationships (1) between the risks of multiple T2DM complications, (2) between the different risk factors, and (3) between the risk factor selection patterns, which assumes similar complications have similar contributing risk factors. The method uses coefficient shrinkage to identify an informative subset of risk factors from high-dimensional data, and uses a hierarchical Bayesian framework to allow domain knowledge to be incorporated as priors. The proposed method is favorable for healthcare applications because in additional to improved prediction performance, relationships among the different risks and risk factors are also identified. Extensive experimental results on a large electronic medical claims database show that the proposed method outperforms state-of-the-art models by a significant margin.
1 September 2011 in IBM Journal of Research and Development
A medical case, as defined by the medical field, is the fundamental building block of medical knowledge. We combine the concept of medical case with indirect evidence from similar patients so as to enable the performance of CER (comparative effectiveness research) treatment comparisons for personalization of medical care. We propose that the vehicle by which this goal is achieved is provided by the integration of case-based reasoning and CER considerations. We discuss the challenges involved and propose a roadmap for creating scientifically sound real-world evidence for assisting personalized treatment decisions.